EyePoint (EYPT) Cash from Financing Activities (2011 - 2026)

EyePoint (EYPT) reported Cash from Financing Activities of -$2.6 million for Q1 2026, down 174.87% on a YoY basis from $3.5 million in Q1 2025, and down 101.57% sequentially from $167.0 million in Q4 2025.

EyePoint (EYPT) Cash from Financing Activities (2011 - 2026) Analysis & Trends

EyePoint (EYPT) has 16 years of Cash from Financing Activities data on file, last reported at -$2.6 million in Q1 2026.

  • For the quarter ending Q1 2026, Cash from Financing Activities fell 174.87% year-over-year to -$2.6 million; the trailing twelve-month figure through Mar 2026 stood at $172.0 million (up 5.54% YoY), and the FY2025 full-year result was $173.6 million, up 5.87% from the prior year.
  • Cash from Financing Activities fell to -$2.6 million in Q1 2026, from $167.0 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $218.5 million in Q4 2023 to a low of -$36.7 million in Q2 2023.
  • A 5-year average of $30.7 million and a median of $115000.0 in 2024 frame the typical range for Cash from Financing Activities.
  • Peak annual rise in Cash from Financing Activities reached 376798.28% in 2023, while the deepest fall reached 13181.88% in 2023.
  • Tracing EYPT's Cash from Financing Activities over 5 years: stood at -$58000.0 in 2022, then surged by 376798.28% to $218.5 million in 2023, then plunged by 30.57% to $151.7 million in 2024, then advanced by 10.07% to $167.0 million in 2025, then sank by 101.57% to -$2.6 million in 2026.
  • Business Quant data shows EYPT's Cash from Financing Activities at -$2.6 million in Q1 2026, $167.0 million in Q4 2025, and $7.4 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 30.14 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 68.63 Mn
4 NuCana 279.75 Bn 279.75 Bn - 9,311.16
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -538.80 Mn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -802.20 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - 238.74 Mn
10 EyePoint 358.61 Mn 136.07 Mn 168,000.00 -2.61 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -2.61 Mn
Mar 31, 2026 -2.61 Mn
Dec 31, 2025 166.96 Mn
Dec 31, 2025 166.96 Mn
Sep 30, 2025 7.40 Mn
Sep 30, 2025 7.40 Mn
Jun 30, 2025 238,000.00
Jun 30, 2025 238,000.00
Mar 31, 2025 -951,000.00
Mar 31, 2025 -951,000.00
Dec 31, 2024 151.69 Mn
Dec 31, 2024 151.69 Mn
Sep 30, 2024 11.89 Mn
Sep 30, 2024 11.89 Mn
Jun 30, 2024 329,000.00
Jun 30, 2024 329,000.00
Mar 31, 2024 115,000.00
Mar 31, 2024 115,000.00
Dec 31, 2023 218.49 Mn
Dec 31, 2023 218.49 Mn